STOCK TITAN
  1. Home
  2. News
  3. RSLS

ReShape Lifesciences Inc. - RSLS STOCK NEWS

Welcome to our dedicated news page for ReShape Lifesciences (Ticker: RSLS), a resource for investors and traders seeking the latest updates and insights on ReShape Lifesciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ReShape Lifesciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ReShape Lifesciences's position in the market.

News
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
ReShape Lifesciences Inc. (RSLS) reported financial results for Q4 and FY 2023, highlighting the completion of first surgeries with the next-generation Lap-Band® 2.0 FLEX. Operating expenses are expected to decrease by over 50% in 2024. The company strengthened its IP portfolio, received FDA approval for Lap-Band® 2.0 FLEX, and engaged in strategic partnerships. Despite revenue decline due to GLP-1 prescriptions, cost reduction plans aim to enhance profitability and commercialize Lap-Band® products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
earnings
-
News
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
Rhea-AI Summary
ReShape Lifesciences (RSLS) receives a Notice of Allowance from the USPTO for a patent application covering an intragastric balloon system, strengthening the company's intellectual property portfolio. The patent will provide protection until at least January 2031, showcasing the company's commitment to innovation and protection of its products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
none
-
News
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
Rhea-AI Summary
ReShape Lifesciences (RSLS) announces a 55.4% decrease in operating expenses for 2024 compared to 2023, focusing on commercializing Lap-Band® 2.0 FLEX and seeking synergistic M&A opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.75%
Tags
none
News
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
Rhea-AI Summary
ReShape Lifesciences (RSLS) announces successful surgeries using Lap-Band® 2.0 FLEX, designed to enhance patient experience. Surgeon training underway. The new FLEX technology aims to improve comfort and eliminate the need for in-office band adjustments, potentially increasing demand for Lap-Band® surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
none
-
News
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
Rhea-AI Summary
ReShape Lifesciences (RSLS) introduces Lap-Band® 2.0 FLEX to bariatric surgical fellows at the University of Texas Health Center, aiming to train the next generation of surgeons on the benefits of the device. The new technology is designed to improve the patient experience by allowing larger pieces of food to pass through the narrowed passage created by the band. The company believes that the Lap-Band® System offers a safe and enduring weight loss solution for patients struggling with managing their weight and is committed to expanding its visibility in the bariatric market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
none
-
News
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
Rhea-AI Summary
ReShape Lifesciences Inc. (Nasdaq: RSLS) has engaged Maxim Group LLC as its exclusive financial advisor to explore potential strategic merger and acquisition partnership alternatives. The company has not set a defined timeline for this transaction and cannot guarantee if or when any transaction will occur.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
partnership
News
ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX
Rhea-AI Summary
ReShape Lifesciences (RSLS) has received FDA approval for its next generation Lap-Band® 2.0 FLEX, designed to improve the patient experience. The FLEX Technology acts as a relief valve, allowing larger pieces of food to more easily pass through the narrowed passage created by the band. The company is preparing for the U.S. product launch and expects this to be a key growth catalyst for its Lap-Band® franchise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
52.99%
Tags
none
-
News
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
Rhea-AI Summary
ReShape Lifesciences, Inc. (RSLS) announces an agreement to exercise outstanding warrants with an investor, resulting in the purchase of 5,382,500 shares of common stock and issuance of new unregistered warrants for 10,765,000 shares. The exercise price of the warrants has been reduced to $0.23, and the new warrants will become exercisable six months following issuance. The company will seek stockholder approval for potential further reduction of the exercise price. The gross proceeds from the exercise of the existing warrants was approximately $1.2 million, with the net proceeds intended for commercial growth, working capital, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
none
-
News
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
Rhea-AI Summary
ReShape Lifesciences Inc. (Nasdaq: RSLS) reported a 37% reduction in core operating expenses compared to the third quarter of 2022. A cost reduction plan aims to cut operating expenses by over 40% in 2024 compared to 2023. The company also highlighted a recent exclusive licensing agreement, a strengthened patent portfolio, and a successful public offering. The CEO emphasized the impact of GLP-1 adoption on the medical weight loss market and the company's strategic measures to address this, including significant cost cuts and investment in growth drivers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.06%
Tags
earnings
News
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
Rhea-AI Summary
ReShape Lifesciences Inc. will report its financial results for Q3 2023 on November 8, 2023. The company will also provide a corporate update. A conference call will be held at 5:00 pm ET on November 8, with a live webcast available on the company's website. Participants can access the call by phone and an archived replay will be available on the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
earnings
Stock RSLS logo
ReShape Lifesciences Inc.

Nasdaq:RSLS

RSLS Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

RSLS Stock Data

3.86M
20.82M
11.16%
1.97%
3.11%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Carlsbad

About RSLS

reshape medical is a development-stage medical device manufacturer headquartered in southern california. the company is focused on the development of non-surgical weight loss devices that can be used as aids in the treatment of obese or overweight patients. there are millions of people looking for a solution to assist them in their battle to lose weight, but many are afraid of the risks of surgery. previously, few if any options existed between drugs for weight loss and invasive surgical restructuring of the anatomy. reshape medical intends to broaden the options and is developing less invasive devices for weight loss treatment.